Online inquiry

IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3416MR)

This product GTTS-WQ3416MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALB gene. The antibody can be applied in Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213
UniProt ID P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3416MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12503MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ362MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ2086MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ10125MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ5001MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ6390MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ8663MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ11300MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW